IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
38.41
-0.20 (-0.52%)
At close: Sep 18, 2026, 4:00 PM EDT
37.00
-1.41 (-3.67%)
After-hours: Sep 18, 2026, 7:30 PM EDT
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, IDEAYA Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $52.38. The average 1-year stock price forecast is 36.37% higher than the current stock price, while the lowest is $31 (-19.29%) and the highest is $65 (+69.23%).
Price Target: $52.38 (+36.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 11 | 11 | 11 | 11 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 16 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $58 | Buy | Maintains | $58 | +51.00% | Sep 18, 2026 |
| Citi | Citi | Buy Maintains $65 | Buy | Maintains | $65 | +69.23% | Sep 11, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $54 → $57 | Buy | Maintains | $54 → $57 | +48.40% | Sep 9, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $50 | Buy | Maintains | $50 | +30.17% | Sep 1, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 1, 2026 |
Financial Forecast
Revenue This Year
39.36M
from 218.71M
Decreased by -82.01%
Revenue Next Year
115.49M
from 39.36M
Increased by 193.45%
EPS This Year
-4.61
from -1.28
EPS Next Year
-4.10
from -4.61
EPS and Forward PE are based on non-GAAP adjusted numbers.